<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36815949</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2023</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Downregulation of miR-137 Facilitates CD4+ T Cell Pyroptosis in Systemic Lupus Erythematosus via Stimulating AMPK Pathway.</ArticleTitle><Pagination><StartPage>1241774</StartPage><MedlinePgn>1241774</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1241774</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2023/1241774</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">From the pathogenic mechanism point of view, systemic lupus erythematosus (SLE) features prominently in T lymphocyte apoptosis. Yet the regulatory mechanism underlying SLE cell apoptosis remains to be explored. This research intends to clarify the role played by miR-137 in SLE and the underlying mechanisms.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Twenty SLE patients (SLE group) and twenty healthy controls (control group) were selected, from whom peripheral blood CD4+ T cells were isolated via magnetic-activated cell sorting. Reverse transcription-polymerase chain reaction (RT-PCR) quantified miR-137 and AMP-activated protein kinase (AMPK) in CD4+ T cells. Further, transfection of miR-137 mimics and inhibitors into CD4+ T cells was carried out to alter miR levels. Levels of pyroptosis, apoptosis, and inflammatory- and pyroptosis-related proteins were determined through PI staining, flow cytometry, and Western blotting, respectively. A luciferase reporter gene assay identified the targeting relation between miR-137 and AMPK.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">SLE patients showed downregulated miR-137 and upregulated AMPK in CD4+ T cells than controls. miR-137 upregulation by miR-137 mimic transfection inhibited Jurkat cell pyroptosis and apoptosis at both mRNA and protein levels and suppressed NOD-like receptor thermal protein domain-associated protein 3 (NLRP3) inflammasome activity and pyroptosis-related protein gasdermin D (GSDMD), while miR-137 inhibitor transfection contributed to completely opposite effects. miR-137 directly targeted AMPK, as indicated by the luciferase reporter gene assay. Furthermore, miR-137 inhibitor intervention induced healthy CD4+ T cell pyroptosis and apoptosis via mediating AMPK, whereas miR-137 mimic transfection into CD4+ T cells of SLE patients leads to opposite results.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Upregulating miR-137 inhibits CD4+ T cell pyroptosis in SLE patients by modulating the AMPK pathway, suggesting the potential diagnostic and therapeutic role of miR-137 in SLE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Aimin Gong et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Aimin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1558-1250</Identifier><AffiliationInfo><Affiliation>Department of Basic Theory of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Hainan Medical University, Haikou, 571199 Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mi</LastName><ForeName>Long</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, The First Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou, 570100 Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Fangzhi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Basic Theory of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Hainan Medical University, Haikou, 571199 Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Yanping</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6520-1813</Identifier><AffiliationInfo><Affiliation>Department of Basic Theory of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Hainan Medical University, Haikou, 571199 Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yitian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Academic Affairs Office, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570311 Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chengdan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Basic Theory of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Hainan Medical University, Haikou, 571199 Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Basic Theory of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Hainan Medical University, Haikou, 571199 Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Guiling</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Basic Theory of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Hainan Medical University, Haikou, 571199 Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhiquan</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-4397-086X</Identifier><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Sanya Central Hospital, Sanya, 572000 Hainan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9528-9366</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311 Hainan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.31</RegistryNumber><NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545567">MIRN137 microRNA, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069292" MajorTopicYN="N">Pyroptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>9</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36815949</ArticleId><ArticleId IdType="pmc">PMC9936506</ArticleId><ArticleId IdType="doi">10.1155/2023/1241774</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shiraishi M., Clowse M. Systemic lupus erythematosus. Annals of Internal Medicine . 2012;159:163&#x2013;348. doi: 10.1159/000336415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000336415</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall'Era M., Cisternas M. G., Snipes K., Herrinton L. J., Gordon C., Helmick C. G. The incidence and prevalence of systemic lupus erythematosus in San Francisco county, California: the California Lupus Surveillance Project. Arthritis &amp; Rheumatology . 2017;69(10):1996&#x2013;2005. doi: 10.1002/art.40191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40191</ArticleId><ArticleId IdType="pubmed">28891237</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly P. M., Wan I., Sahl S., et al. The incidence and prevalence of systemic lupus erythematosus in New York county (Manhattan), New York: the Manhattan Lupus Surveillance Program. Arthritis &amp; Rheumatology . 2017;69(10):2006&#x2013;2017. doi: 10.1002/art.40192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40192</ArticleId><ArticleId IdType="pubmed">28891252</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M. Epidemiology of systemic lupus erythematosus. Best Practice &amp; Research Clinical Rheumatology . 2002;16(5):847&#x2013;858. doi: 10.1053/berh.2002.0259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/berh.2002.0259</ArticleId><ArticleId IdType="pubmed">12473278</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees F., Doherty M., Grainge M. J., Lanyon P., Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology . 2017;56(11):1945&#x2013;1961. doi: 10.1093/rheumatology/kex260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex260</ArticleId><ArticleId IdType="pubmed">28968809</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter E. E., Barr S. G., Clarke A. E. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nature Reviews Rheumatology . 2016;12(10):605&#x2013;620. doi: 10.1038/nrrheum.2016.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.137</ArticleId><ArticleId IdType="pubmed">27558659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y., Choi S., Ji J., Song G. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus . 2016;25(7):727&#x2013;734. doi: 10.1177/0961203315627202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315627202</ArticleId><ArticleId IdType="pubmed">26811368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohl K., Tenbrock K. Regulatory T cells in systemic lupus erythematosus. European Journal of Immunology . 2015;45(2):344&#x2013;355. doi: 10.1002/eji.201344280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201344280</ArticleId><ArticleId IdType="pubmed">25378177</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaier M., Gottschalk C., K&#xe4;lble F., et al. The onset of active disease in systemic lupus erythematosus patients is characterised by excessive regulatory CD4+-T-cell differentiation. Clinical and Experimental Rheumatology . 2021;39:279&#x2013;288. doi: 10.55563/clinexprheumatol/cg29xj.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/cg29xj</ArticleId><ArticleId IdType="pubmed">32573411</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui C., Wang J., Fagerberg E., et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell . 2021;184(25):6101&#x2013;6118.e13. doi: 10.1016/j.cell.2021.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.11.007</ArticleId><ArticleId IdType="pmc">PMC8671355</ArticleId><ArticleId IdType="pubmed">34852236</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruterbusch M., Pruner K. B., Shehata L., Pepper M. In vivo CD4+ T cell differentiation and function: revisiting the Th1/Th2 paradigm. Annual Review of Immunology . 2020;38(1):705&#x2013;725. doi: 10.1146/annurev-immunol-103019-085803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-103019-085803</ArticleId><ArticleId IdType="pubmed">32340571</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera-Esparza R., Herrera-van-Oostdam D., L&#xf3;pez-Robles E., Avalos-D&#xed;az E. The role of apoptosis in autoantibody production. Reumatismo . 2007;59(2):87&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17603689</ArticleId></ArticleIdList></Reference><Reference><Citation>Zawrotniak M., Rapala-Kozik M. Neutrophil extracellular traps (NETs)-formation and implications. Acta Biochimica Polonica . 2013;60(3):277&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">23819131</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay S. H., Celhar T., Fairhurst A. M. Low-density neutrophils in systemic lupus erythematosus. Arthritis &amp; Rheumatology . 2020;72(10):1587&#x2013;1595. doi: 10.1002/art.41395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41395</ArticleId><ArticleId IdType="pmc">PMC7590095</ArticleId><ArticleId IdType="pubmed">32524751</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson B. T., Brennan M. A. Pro-inflammatory programmed cell death. Trends in Microbiology . 2001;9(3):113&#x2013;114. doi: 10.1016/S0966-842X(00)01936-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0966-842X(00)01936-3</ArticleId><ArticleId IdType="pubmed">11303500</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao E. A., Leaf I. A., Treuting P. M., et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nature Immunology . 2010;11(12):1136&#x2013;1142. doi: 10.1038/ni.1960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1960</ArticleId><ArticleId IdType="pmc">PMC3058225</ArticleId><ArticleId IdType="pubmed">21057511</ArticleId></ArticleIdList></Reference><Reference><Citation>Doitsh G., Galloway N. L., Geng X., et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature . 2014;505(7484):509&#x2013;514. doi: 10.1038/nature12940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12940</ArticleId><ArticleId IdType="pmc">PMC4047036</ArticleId><ArticleId IdType="pubmed">24356306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskaran M., Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Veterinary Pathology . 2014;51(4):759&#x2013;774. doi: 10.1177/0300985813502820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300985813502820</ArticleId><ArticleId IdType="pmc">PMC4013251</ArticleId><ArticleId IdType="pubmed">24045890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Pedrera C., Barbarroja N., Pati&#xf1;o-Trives A. M., et al. Role of microRNAs in the development of cardiovascular disease in systemic autoimmune disorders. International Journal of Molecular Sciences . 2020;21(6):p. 2012. doi: 10.3390/ijms21062012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21062012</ArticleId><ArticleId IdType="pmc">PMC7139533</ArticleId><ArticleId IdType="pubmed">32188016</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu Z., Li W., Fu B. MicroRNAs in autoimmune diseases. BioMed Research International . 2014;2014:8. doi: 10.1155/2014/527895.527895</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/527895</ArticleId><ArticleId IdType="pmc">PMC4065654</ArticleId><ArticleId IdType="pubmed">24991561</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Guo Y., Sun Y., Chang L., Wang X. Inhibition of microRNA-448 suppresses CD4+ T cell inflammatory activation via up-regulating suppressor of cytokine signaling 5 in systemic lupus erythematosus. Biochemical and Biophysical Research Communications . 2022;596:88&#x2013;96. doi: 10.1016/j.bbrc.2022.01.097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2022.01.097</ArticleId><ArticleId IdType="pubmed">35121374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhang Z., Liang H., Chen R., Huang Y. Circ_0025908 regulates cell vitality and proliferation via miR-137/HIPK2 axis of rheumatic arthritis. Journal of Orthopaedic Surgery and Research . 2021;16(1):1&#x2013;11. doi: 10.1186/s13018-021-02615-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-021-02615-y</ArticleId><ArticleId IdType="pmc">PMC8323297</ArticleId><ArticleId IdType="pubmed">34330307</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgebaly S. A., Christenson R. H., Kandil H., et al. Nourin-dependent miR-137 and miR-106b: novel early inflammatory diagnostic biomarkers for unstable angina patients. Biomolecules . 2021;11(3):p. 368. doi: 10.3390/biom11030368.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11030368</ArticleId><ArticleId IdType="pmc">PMC7997347</ArticleId><ArticleId IdType="pubmed">33670982</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoki K., Kim J., Guan K.-L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annual Review of Pharmacology and Toxicology . 2012;52(1):381&#x2013;400. doi: 10.1146/annurev-pharmtox-010611-134537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010611-134537</ArticleId><ArticleId IdType="pubmed">22017684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross F. A., MacKintosh C., Hardie D. G. AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours. The FEBS Journal . 2016;283(16):2987&#x2013;3001. doi: 10.1111/febs.13698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.13698</ArticleId><ArticleId IdType="pmc">PMC4995730</ArticleId><ArticleId IdType="pubmed">26934201</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardie D. G., Schaffer B. E., Brunet A. AMPK: an energy-sensing pathway with multiple inputs and outputs. Trends in Cell Biology . 2016;26(3):190&#x2013;201. doi: 10.1016/j.tcb.2015.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2015.10.013</ArticleId><ArticleId IdType="pmc">PMC5881568</ArticleId><ArticleId IdType="pubmed">26616193</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubser P. M., Bantug G. R., Razik L., et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nature Immunology . 2013;14(10):1064&#x2013;1072. doi: 10.1038/ni.2687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2687</ArticleId><ArticleId IdType="pubmed">23955661</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao E., Zhang Y., Li Q., et al. AMPK-dependent and independent effects of AICAR and compound C on T-cell responses. Oncotarget . 2016;7(23):33783&#x2013;33795. doi: 10.18632/oncotarget.9277.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.9277</ArticleId><ArticleId IdType="pmc">PMC5085118</ArticleId><ArticleId IdType="pubmed">27177226</ArticleId></ArticleIdList></Reference><Reference><Citation>Day E. A., Ford R. J., Steinberg G. R. AMPK as a therapeutic target for treating metabolic diseases. Trends in Endocrinology &amp; Metabolism . 2017;28(8):545&#x2013;560. doi: 10.1016/j.tem.2017.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2017.05.004</ArticleId><ArticleId IdType="pubmed">28647324</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg G. R., Schertzer J. D. AMPK promotes macrophage fatty acid oxidative metabolism to mitigate inflammation: implications for diabetes and cardiovascular disease. Immunology and Cell Biology . 2014;92(4):340&#x2013;345. doi: 10.1038/icb.2014.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2014.11</ArticleId><ArticleId IdType="pubmed">24638063</ArticleId></ArticleIdList></Reference><Reference><Citation>Trefts E., Shaw R. J. AMPK: restoring metabolic homeostasis over space and time. Molecular Cell . 2021;81(18):3677&#x2013;3690. doi: 10.1016/j.molcel.2021.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2021.08.015</ArticleId><ArticleId IdType="pmc">PMC8549486</ArticleId><ArticleId IdType="pubmed">34547233</ArticleId></ArticleIdList></Reference><Reference><Citation>Salt I. P., Palmer T. M. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opinion on Investigational Drugs . 2012;21(8):1155&#x2013;1167. doi: 10.1517/13543784.2012.696609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.2012.696609</ArticleId><ArticleId IdType="pubmed">22694351</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardie D. G., Ross F. A., Hawley S. A. AMP-activated protein kinase: a target for drugs both ancient and modern. Chemistry &amp; Biology . 2012;19(10):1222&#x2013;1236. doi: 10.1016/j.chembiol.2012.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2012.08.019</ArticleId><ArticleId IdType="pmc">PMC5722193</ArticleId><ArticleId IdType="pubmed">23102217</ArticleId></ArticleIdList></Reference><Reference><Citation>Gejjalagere Honnappa C., Mazhuvancherry Kesavan U. A concise review on advances in development of small molecule anti-inflammatory therapeutics emphasising AMPK: an emerging target. International Journal of Immunopathology and Pharmacology . 2016;29(4):562&#x2013;571. doi: 10.1177/0394632016673369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0394632016673369</ArticleId><ArticleId IdType="pmc">PMC5806819</ArticleId><ArticleId IdType="pubmed">27707958</ArticleId></ArticleIdList></Reference><Reference><Citation>Agius L., Ford B. E., Chachra S. S. The metformin mechanism on gluconeogenesis and AMPK activation: the metabolite perspective. International Journal of Molecular Sciences . 2020;21(9):p. 3240. doi: 10.3390/ijms21093240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093240</ArticleId><ArticleId IdType="pmc">PMC7247334</ArticleId><ArticleId IdType="pubmed">32375255</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Fang L., Ye L., et al. miR-137 targets the inhibition of TCF4 to reverse the progression of osteoarthritis through the AMPK/NF-&#x3ba;B signaling pathway. Bioscience Reports . 2020;40(6):p. BSR20200466. doi: 10.1042/BSR20200466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20200466</ArticleId><ArticleId IdType="pmc">PMC7295621</ArticleId><ArticleId IdType="pubmed">32432314</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y., Choi S.-C., Xu Z., et al. Normalization of CD4+ T cell metabolism reverses lupus. Science Translational Medicine . 2015;7(274):p. 274ra18. doi: 10.1126/scitranslmed.aaa0835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa0835</ArticleId><ArticleId IdType="pmc">PMC5292723</ArticleId><ArticleId IdType="pubmed">25673763</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank D., Vince J. E. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death &amp; Differentiation . 2019;26(1):99&#x2013;114. doi: 10.1038/s41418-018-0212-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-018-0212-6</ArticleId><ArticleId IdType="pmc">PMC6294779</ArticleId><ArticleId IdType="pubmed">30341423</ArticleId></ArticleIdList></Reference><Reference><Citation>Essandoh K., Li Y., Huo J., Fan G.-C. miRNA-mediated macrophage polarization and its potential role in the regulation of inflammatory response. Shock (Augusta, Ga.) . 2016;46(2):122&#x2013;131. doi: 10.1097/SHK.0000000000000604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000604</ArticleId><ArticleId IdType="pmc">PMC4949115</ArticleId><ArticleId IdType="pubmed">26954942</ArticleId></ArticleIdList></Reference><Reference><Citation>Amarilyo G., La Cava A. miRNA in systemic lupus erythematosus. Clinical Immunology . 2012;144(1):26&#x2013;31. doi: 10.1016/j.clim.2012.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2012.04.005</ArticleId><ArticleId IdType="pubmed">22659032</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Ji Y., Wang X., et al. Relationship of miRNA-146a to systemic lupus erythematosus: a prisma-compliant meta-analysis. Medicine . 2020;99(40, article e22444) doi: 10.1097/MD.0000000000022444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000022444</ArticleId><ArticleId IdType="pmc">PMC7535641</ArticleId><ArticleId IdType="pubmed">33019429</ArticleId></ArticleIdList></Reference><Reference><Citation>Obad S., Orum H. Miravirsen sodium. miR-122 inhibitor, treatment of hepatitis C virus infection. Drugs of the Future . 2013;38(6):367&#x2013;373. doi: 10.1358/dof.2013.038.06.1971489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/dof.2013.038.06.1971489</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Campbell F., Han K., et al. Randomized clinical trials towards a single-visit cure for chronic hepatitis C: oral GSK2878175 and injectable rg-101 in chronic hepatitis c patients and long-acting injectable GSK2878175 in healthy participants. Journal of Viral Hepatitis . 2020;27(7):699&#x2013;708. doi: 10.1111/jvh.13282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvh.13282</ArticleId><ArticleId IdType="pubmed">32096313</ArticleId></ArticleIdList></Reference><Reference><Citation>Suo Q. F., Sheng J., Qiang F. Y., Tang Z. S., Yang Y. Y. Association of long non-coding RNA gas5 and miR-21 levels in CD4+ T cells with clinical features of systemic lupus erythematosus. Experimental and Therapeutic Medicine . 2018;15(1):345&#x2013;350. doi: 10.3892/etm.2017.5429.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2017.5429</ArticleId><ArticleId IdType="pmc">PMC5769282</ArticleId><ArticleId IdType="pubmed">29387192</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L., Xu J. Role of miR-98 and its underlying mechanisms in systemic lupus erythematosus. The Journal of Rheumatology . 2018;45(10):1397&#x2013;1405. doi: 10.3899/jrheum.171290.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.171290</ArticleId><ArticleId IdType="pubmed">29907673</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Zhang Z., Ruan J., et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature . 2016;535(7610):153&#x2013;158. doi: 10.1038/nature18629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18629</ArticleId><ArticleId IdType="pmc">PMC5539988</ArticleId><ArticleId IdType="pubmed">27383986</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J., Wang K., Liu W., et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature . 2016;535(7610):111&#x2013;116. doi: 10.1038/nature18590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18590</ArticleId><ArticleId IdType="pubmed">27281216</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Zhao Y., Wang K., et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature . 2015;526(7575):660&#x2013;665. doi: 10.1038/nature15514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15514</ArticleId><ArticleId IdType="pubmed">26375003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y., Cui R., Wang C., et al. Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway. Redox Biology . 2020;32, article 101534 doi: 10.1016/j.redox.2020.101534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2020.101534</ArticleId><ArticleId IdType="pmc">PMC7178548</ArticleId><ArticleId IdType="pubmed">32330868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bairwa S. C., Parajuli N., Dyck J. R. The role of AMPK in cardiomyocyte health and survival. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease . 2016;1862(12):2199&#x2013;2210. doi: 10.1016/j.bbadis.2016.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.07.001</ArticleId><ArticleId IdType="pubmed">27412473</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X., Yang T., Liu G., Liu H., Peng Y., He L. Piperine ameliorated lupus nephritis by targeting AMPK-mediated activation of NLRP3 inflammasome. International Immunopharmacology . 2018;65:448&#x2013;457. doi: 10.1016/j.intimp.2018.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.10.025</ArticleId><ArticleId IdType="pubmed">30388519</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths H. R., Gao D., Pararasa C. Redox regulation in metabolic programming and inflammation. Redox Biology . 2017;12:50&#x2013;57. doi: 10.1016/j.redox.2017.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.01.023</ArticleId><ArticleId IdType="pmc">PMC5312548</ArticleId><ArticleId IdType="pubmed">28212523</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Huang L., Shi X., et al. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway. Aging (Albany NY) . 2020;12(23):24270&#x2013;24287. doi: 10.18632/aging.202143.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.202143</ArticleId><ArticleId IdType="pmc">PMC7762510</ArticleId><ArticleId IdType="pubmed">33232283</ArticleId></ArticleIdList></Reference><Reference><Citation>Melemedjian O. K., Asiedu M. N., Tillu D. V., et al. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Molecular Pain . 2011;7:1744&#x2013;8069. doi: 10.1186/1744-8069-7-70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1744-8069-7-70</ArticleId><ArticleId IdType="pmc">PMC3186752</ArticleId><ArticleId IdType="pubmed">21936900</ArticleId></ArticleIdList></Reference><Reference><Citation>Leu C.-M., Hsu T.-S., Kuo Y.-P., et al. Deltex1 suppresses T cell function and is a biomarker for diagnosis and disease activity of systemic lupus erythematosus. Rheumatology . 2019;58(4):719&#x2013;728. doi: 10.1093/rheumatology/key418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key418</ArticleId><ArticleId IdType="pubmed">30629240</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>